Archive

▤ Summary

Ocumetics announced that debentureholders converted $1.4 million of principal into common shares, cutting its outstanding debenture balance by 35%. The company says the move strengthens its balance sheet and lowers interest costs as it advances its patient study program. Ocumetics also highlighted progress toward regulatory work, including preparation for an Investigational Device Exemption submission to the U.S. FDA. The company positions this financing step as support for its ongoing clinical and product development milestones.

$ Funding

▦ Linked Companies